US Glioma Diagnosis Treatment Market: How Are IDH Inhibitors Creating New Targeted Therapy Markets?
IDH inhibitor therapy for IDH-mutant glioma — the first targeted molecular therapy approved for IDH-mutant gliomas representing the precision oncology breakthrough that the molecular era of glioma classification has enabled — creates a new and growing commercial market, with the US Glioma Diagnosis Treatment Market reflecting IDH-targeted therapy as the most important recent...
0 Comments 0 Shares 68 Views 0 Reviews
Sponsored